Daratumumab significantly extends PFS in multiple myeloma study10 June 2016 | By Victoria White, Digital Content ProducerA Phase III trial shows daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in the risk of disease progression or death...
Venetoclax shown to be effective in CLL patients who relapse or are refractory10 June 2016 | ByNew data show promising results for venetoclax in patients with chronic lymphocytic leukaemia who have relapsed or become refractory (R/R) to treatment...
Bimekizumab demonstrates positive results in patients with psoriatic arthritis10 June 2016 | By Victoria White, Digital Content ProducerIn a Phase Ib study, bimekizumab showed fast and sustained efficacy on disease activity measures in both skin and joints and was well-tolerated...
New data for baricitinib in rheumatoid arthritis presented at EULAR9 June 2016 | By Victoria White (European Pharmaceutical Review)Lilly and Incyte have announced new data for baricitinib in rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016).
Efficacy and safety of Biogen’s anti-TNF biosimilars presented at EULAR9 June 2016 | By Victoria White, Digital Content ProducerData demonstrating long-term comparable efficacy, safety and immunogenicity of Benepali (etanercept) and Flixabi (infliximab) have been presented at EULAR...
Promising Phase I/II results for GenSight’s GS010 in LHON9 June 2016 | By Victoria White, Digital Content ProducerThe Phase I/II study was designed to demonstrate the safety and tolerability of GS010 in 15 patients with Leber’s Hereditary Optic Neuropathy...
New Managed Access programme for isavuconazole9 June 2016 | By Victoria White, Digital Content ProducerThe programme will enable patients with serious fungal infections in EU states where the treatment is not yet commercially available to access isavuconazole...
AMG 334 significantly reduces monthly migraine days in study9 June 2016 | By Victoria White, Digital Content ProducerNovartis has announced positive first results from a Phase II investigating the efficacy and safety of AMG 334 (erenumab) in chronic migraine prevention...
AGI acquires rights to AstraZeneca’s anaesthetics portfolio outside US9 June 2016 | By Victoria White, Digital Content ProducerAGI is to acquire the rights, outside the US, to AstraZeneca’s portfolio of anaesthetics for an upfront consideration of $520 million...
Bristol-Myers Squibb shares significant new findings in rheumatoid arthritis research8 June 2016 | By Mandy Parrett, Editorial AssistantGlobal biopharma company, Bristol-Myers Squibb, will present new data and offer insights into the field of rheumatoid arthritis at the Annual European Congress of Rheumatology (EULAR 2016) this week.
Greater response with GSK’s Benlysta vs placebo in SLE study8 June 2016 | By Victoria White, Digital Content ProducerPatients with SLE experienced a significantly greater response to treatment with Benlysta administered via subcutaneous injection compared to placebo...
Sirukumab meets both co-primary endpoints in rheumatoid arthritis study8 June 2016 | By Victoria White, Digital Content ProducerThe SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis...
Novartis plans head-to-head studies of Cosentyx versus Humira8 June 2016 | By Victoria White, Digital Content ProducerLong-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
EC approves Avastin plus Tarceva in NSCLC8 June 2016 | By Victoria White, Digital Content ProducerThe combination is approved for the first-line treatment of adult patients with non-squamous NSCLC with EGFR-activating mutations...
Positive top-line results for tofacitinib citrate in active psoriatic arthritis8 June 2016 | By Victoria White, Digital Content ProducerThe OPAL Beyond study met its primary efficacy endpoints demonstrating a statistically significant improvement with tofacitinib 5 mg BID and 10 mg BID...
